Literature DB >> 28159534

Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen.

Felicity J Burt1, Weiqiang Chen2, Jonathan J Miner3, Deborah J Lenschow3, Andres Merits4, Esther Schnettler5, Alain Kohl6, Penny A Rudd2, Adam Taylor2, Lara J Herrero2, Ali Zaid2, Lisa F P Ng7, Suresh Mahalingam2.   

Abstract

Re-emergence of chikungunya virus, a mosquito-transmitted pathogen, is of serious public health concern. In the past 15 years, after decades of infrequent, sporadic outbreaks, the virus has caused major epidemic outbreaks in Africa, Asia, the Indian Ocean, and more recently the Caribbean and the Americas. Chikungunya virus is mainly transmitted by Aedes aegypti mosquitoes in tropical and subtropical regions, but the potential exists for further spread because of genetic adaptation of the virus to Aedes albopictus, a species that thrives in temperate regions. Chikungunya virus represents a substantial health burden to affected populations, with symptoms that include severe joint and muscle pain, rashes, and fever, as well as prolonged periods of disability in some patients. The inflammatory response coincides with raised levels of immune mediators and infiltration of immune cells into infected joints and surrounding tissues. Animal models have provided insights into disease pathology and immune responses. Although host innate and adaptive responses have a role in viral clearance and protection, they can also contribute to virus-induced immune pathology. Understanding the mechanisms of host immune responses is essential for the development of treatments and vaccines. Inhibitory compounds targeting key inflammatory pathways, as well as attenuated virus vaccines, have shown some success in animal models, including an attenuated vaccine strain based on an isolate from La Reunion incorporating an internal ribosome entry sequence that prevents the virus from infecting mosquitoes and a vaccine based on virus-like particles expressing envelope proteins. However, immune correlates of protection, as well as the safety of prophylactic and therapeutic candidates, are important to consider for their application in chikungunya infections. In this Review, we provide an update on chikungunya virus with regard to its epidemiology, molecular virology, virus-host interactions, immunological responses, animal models, and potential antiviral therapies and vaccines.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28159534     DOI: 10.1016/S1473-3099(16)30385-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  106 in total

Review 1.  Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases.

Authors:  Rita M Meganck; Ralph S Baric
Journal:  Nat Med       Date:  2021-03-15       Impact factor: 53.440

2.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

Review 3.  Emerging and threatening vector-borne zoonoses in the world and in Europe: a brief update.

Authors:  Eva Jánová
Journal:  Pathog Glob Health       Date:  2019-03-27       Impact factor: 2.894

4.  Atovaquone Inhibits Arbovirus Replication through the Depletion of Intracellular Nucleotides.

Authors:  Angelica Cifuentes Kottkamp; Elfie De Jesus; Rebecca Grande; Julia A Brown; Adam R Jacobs; Jean K Lim; Kenneth A Stapleford
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

5.  High-Throughput Fluorescence-Based Screen Identifies the Neuronal MicroRNA miR-124 as a Positive Regulator of Alphavirus Infection.

Authors:  Paula López; Erika Girardi; Bryan C Mounce; Amélie Weiss; Béatrice Chane-Woon-Ming; Mélanie Messmer; Pasi Kaukinen; Arnaud Kopp; Diane Bortolamiol-Becet; Ali Fendri; Marco Vignuzzi; Laurent Brino; Sébastien Pfeffer
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

6.  Chikungunya Virus Evades Antiviral CD8+ T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues.

Authors:  Bennett J Davenport; Christopher Bullock; Mary K McCarthy; David W Hawman; Kenneth M Murphy; Ross M Kedl; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

Review 7.  How Do Virus-Mosquito Interactions Lead to Viral Emergence?

Authors:  Claudia Rückert; Gregory D Ebel
Journal:  Trends Parasitol       Date:  2018-01-02

Review 8.  Chikungunya fever: a threat to global public health.

Authors:  Raíza Nara Cunha Moizéis; Thales Allyrio Araújo de Medeiros Fernandes; Paulo Marcos da Matta Guedes; Hannaly Wana Bezerra Pereira; Daniel Carlos Ferreira Lanza; Judson Welber Veríssimo de Azevedo; Josélio Maria de Araújo Galvão; José Veríssimo Fernandes
Journal:  Pathog Glob Health       Date:  2018-05-28       Impact factor: 2.894

9.  In silico study of chikungunya polymerase, a potential target for inhibitors.

Authors:  Ritu Ghildiyal; Sanjay Gupta; Reema Gabrani; Gopal Joshi; Amita Gupta; V K Chaudhary; Vandana Gupta
Journal:  Virusdisease       Date:  2019-10-26

10.  A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses.

Authors:  Jesse Hwang; Alfred Jiang; Erol Fikrig
Journal:  Antiviral Res       Date:  2018-12-03       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.